Symbols

LIMN

Liminatus Pharma·NASDAQ

--(--)

7.10 / 10

Outperform

Analyst coverage is absent (ana_eval -1). Fund‑flow score is 7.1/10, indicating good capital interest, though inflow trends are negative across all size categories. Sentiment remains positive, supporting a cautiously optimistic view despite the lack of analyst guidance.

Fund Flow Rating

What is the analyst consensus for LIMN?

LIMN holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.10/10 (Outperform).